Louis Tassy

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Olivia Bally, Louis Tassy, Bertrand Richioud et al. · Clinical Sarcoma Research · 2015 · 53 citations · Full text

Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees’ organization

Patrick Castel, Louis Tassy, A. Lurkin et al. · Bulletin du Cancer · 2012 · 20 citations

Organizations, Cancer Epidemiology, Medicine +10